Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187485 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01187485: Completed Phase 1 study, sponsored by University of Chicago.
NCT01187485 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01187485, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to see how safe Androderm® (the study drug) is at three different doses in subjects with early hormone refractory prostate cancer. In addition, information about hormonal levels and the effects of testosterone on quality of life including sexual functioning and muscle strength will be collected.
Primary Outcome
To determine the safety of Androderm® 2.5 mg, 5.0 mg, and 7.5 mg in patients with early hormone refractory prostate cancer.
Interventions
- DRUG Androderm® 2.5mg
- DRUG Androderm® 5.0mg
- DRUG Androderm® 7.5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
What the finished NCT01187485 record still lists
NCT01187485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Androderm® 2.5mg is the first listed.
NCT01187485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01187485 about?
NCT01187485 is a clinical study titled "A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer". The purpose of this study is to see how safe Androderm® (the study drug) is at three different doses in subjects with early hormone refractory prostate cancer. In addition, information about hormonal levels and the effects of testosterone on quality of life including sexual functioning and muscle st...
What is the current status of trial NCT01187485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2004-06. Estimated completion is 2009-02.
What interventions are being tested in trial NCT01187485?
The interventions under investigation include: Androderm® 2.5mg (DRUG), Androderm® 5.0mg (DRUG), Androderm® 7.5mg (DRUG).
Who is sponsoring clinical trial NCT01187485?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01187485's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia